Claims for Patent: 9,789,064

Summary for Patent: 9,789,064

Title:	Method for delivering a peptide to a subject at a modulated rate via microcapsules of lactic-co-glycolic copolymer containing said peptide
Abstract:	Micro-capsules for the slow release of drugs, consisting of a lactic-co-glycolic copolymer to which a plasticizer has been incorporated and which contain a drug of pharmaceutical interested within them.
Inventor(s):	Parente Duena; Antonio (Barcelona, ES), Garces Garces; Josep (Barcelona, ES), Bonilla Munoz; Angel (Barcelona, ES), Cunillera Colome; David (Barcelona, ES)
Assignee:	GP PHARM, S.A. (Barcelona, ES)
Application Number:	12/148,893
Patent Claims:	1. A method for delivering a peptide analog of luteinizing hormone releasing, hormone (LHRH) selected from the group consisting of triptorelin, leuprolide, goserelin, buserelin and cetrorelix at a modulated rate to a subject in need thereof, said method comprising: administering to the subject an amount of microcapsules of a polymer selected from a polylactic acid polymer or a lactic-co-glycolic copolymer containing the peptide analog to provide a therapeutic effect, wherein the polymer incorporates triethyl citrate as an additive, wherein the triethyl citrate is added in a range of between 2.7% and 4.4% by total weight of the microcapsule components, and wherein the triethyl citrate produces a modulation of the release of the peptide analog from the microcapsules and a reduction of the initial release rate of the peptide analog from the microcapsules as compared to an identical microcapsule in the absence of triethyl citrate. 2. The method according to claim 1, wherein the polymer is a lactic-co-glycolic copolymer comprising lactate and glycolate units which are present in a ratio of between 99:1 and 10:90, both inclusive. 3. A method for delivering a peptide analog of luteinizing hormone releasing hormone (LHRH) selected from the group consisting of triptorelin, leuprolide, goserelin, buserelin and cetrorelix at a modulated rate to a subject to whom a plurality of microcapsules containing said peptide analog are administered, said method comprising: (a) forming a plurality of microcapsules containing the peptide analog by (i) dissolving a polymer selected from a polylactic acid polymer or a lactic co-glycolic copolymer and triethyl citrate in a solvent in which said polymer and said triethyl citrate are soluble to form a solution; (ii) adding the peptide analog to the solution to form a peptide suspension in said solution; (iii) adding an alkyl derivative to the solution to produce deposition of the polymer and the triethyl citrate on the peptide analog; (iv) adding the suspension obtained in step (ii) to a solution in which said polymer and triethyl citrate are not soluble to harden and precipitate microcapsules thus formed; and (v) isolating the microcapsules thus formed, wherein the polymer incorporates triethyl citrate as an additive, wherein the triethyl citrate is added in a range of between 2.7% and 4.4% by total weight of the microcapsule components, and (b) administering a sufficient amount of said microcapsules containing the peptide analog to provide a therapeutic effect to said subject, wherein the triethyl citrate produces a modulation of the release of the peptide analog from the microcapsules and a reduction of the initial release rate of the peptide analog from the microcapsules as compared to an identical microcapsule in the absence of triethyl citrate. 4. The method according to claim 3, wherein a ratio between lactate and glycolate units in the lactic co-glycolic copolymer is between 99:1 and 10:90, both inclusive. 5. The method according to claim 3, wherein the alkyl derivative is silicon oil. 6. The method according to claim 1, wherein the lactic-co-glycolic copolymer comprises lactate and glycolate units present in a ratio of 1:1. 7. The method according to claim 1, wherein the molecular weight of the lactic-co-glycolic polymer is 50,000. 8. The method according to claim 1, wherein the peptide analog of LHRH is leuprolide. 9. The method according to claim 1, wherein the peptide analog of LHRH is leuprolide acetate. 10. A microcapsule comprising: i. a peptide analog selected from leuprolide, octreotide or triptorelin; ii. a polymer selected from a polylactic acid polymer or a lactic-co-glycolic copolymer containing the peptide analog; and iii. triethyl citrate; wherein the polymer incorporates triethyl citrate as an additive, wherein the triethyl citrate is added in a range of between 2.7% and 4.4% by total weight of the microcapsule components and wherein the triethyl citrate produces a modulation of the release of the peptide analog from the microcapsules and a reduction of the initial release rate of the peptide analog from the microcapsules as compared to an identical microcapsule in the absence of triethyl citrate.